Achieve Life Sciences announced that the final subject of the Company’s Phase 2 ORCA-V1 trial has completed treatment in the study. ORCA-V1 is evaluating the efficacy and safety of cytisinicline in adult users of nicotine e-cigarettes or vapes and is being supported in part through grant funding from the National Institute on Drug Abuse of the National Institutes of Health, The ORCA-V1 trial randomized 160 adult users of nicotine e-cigarettes across 5 clinical trial locations in the United States. Participants were randomized into two arms to either receive 3 mg of cytisinicline three times daily, or placebo, for a period of 12 weeks. Patients also received standardized behavioral support throughout the trial. The primary endpoint is continuous abstinence during the final 4 weeks of treatment. Dr. Nancy Rigotti, Professor of Medicine at Harvard Medical School and Director, Tobacco Research and Treatment Center, Massachusetts General Hospital is the primary investigator for the ORCA-V1 trial.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ACHV:
- Achieve Life Sciences management to meet virtually with Lake Street
- Achieve Life Sciences Announces Granting of New Hire Inducement Award
- Achieve Life Sciences holder Dialectic to engage ‘more actively’
- Biotech Alert: Searches spiking for these stocks today
- Achieve Life Sciences announces last subject dosed in Phase 3 ORCA-3 trial